LCTX · Lineage Cell Therapeutics, Inc.
3.21
ILSUnlock stock Insights
Create a free account to unlock price targets, recommendations, and commentary.
Overview
Market Cap
n/a
PE
0.00
EV/EBITDA
N/A
DIV Yield
0%
Payout Ratio
0%
MQV Rating
5Very Weak
As at 02/10/2026 12:00:00 AM
Price Chart
Description
- All-Companies
- HALO All
Key Fundamentals
EPS 3 yr Growth
83.20%
EBITDA Margin
-144.80%
Operating Cashflow
-₪65m
Free Cash Flow Return
-29.80%
ROIC
-100.20%
Interest Coverage
N/A
Quick Ratio
5.20
Performance
52 weeks range
Low 2.84 - 6.66
Trade Value (12mth)
US$2,807.00
1 week
3.45%
1 month
-1.96%
YTD
-40.15%
1 year
-23.74%
All time high
15.62
Additional Data
Shares Outstanding (Fully Diluted)
261m
HALO Sector
Healthcare
Next Company Report Date
N/A
Next Ex Dividend Date
N/A
Next Dividend Pay Date
N/A
Reporting Currency
ILS
Short Sell (% of issue)
0.00
Health Scores
Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
Mqv
Very Weak
Garp
Very Weak
Mqv Small
Neutral
Momentum
Price
Weak
Earnings
Very Weak
Growth
Earnings
Very Weak
Dividends
Very Weak
Quality
Capital Efficiency
Very Weak
Balance Sheet
Very Weak
Valuation
Value
Consensus
Yield
Key Stakeholders
| Name | Title |
| Broadwood Capital, Inc. | Private Company |
| Jorey Chernett | Individual |
| Michael H. Mulroy | Individual |
| Brian M. Culley | Individual |
| Neal Clifton Bradsher | Individual |
